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Challenges in the development and adaptation of platform process to 
existing pipeline  
Nandita Vishwanathan, Ed Scarfo, Christopher Brown, Christine Collins and 
Chris Campbell 
 
The development and use of platform processes have been adopted as an industry-wide strategy for 
enabling faster timelines for early clinical stages.  However due to increasing product demands and the 
competitive landscape of antibody therapeutics  in the industry,  the development and use of a highly 
productive and economic upstream  platform process has also become an adopted strategy.     In 
keeping with industry standards, Takeda’s platform has evolved from upstream processes capable of 
achieving protein titers from 0.7-1.2 g/L to highly productive processes achieving titers in the range of 
4.0-7.0 g/L.  Unlike these earlier, low titer processes for the same molecules, the platform has also 
evolved to incorporate proprietary process mediums which are protein-free and animal component-free 
. For earlier versions of the newer platform, the concentrations of the feed media components were 
determined by estimating their consumption rates relative to the glucose consumption rate. However, 
this process involved administration of three different feed media being delivered at different times. 
The process was further refined to consolidate feeds for the ease of operation and for the purpose of 
manufacturing process transfer.  
Takeda has amassed a variety of drug candidates over the past few years which have used this newly 
refined platform. However, each drug candidate can present unique challenges of expression, 
production and quality characteristics, during adaptation to our platform process. Our approach towards 
achieving consistency in critical product quality attributes using media additives and process 
adjustments will be presented. Such challenges and a history of evolution for the platform process for 
three different candidates will be discussed. 
